Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese subjects with type 1 diabetes mellitus reflect similarities with Caucasian subjects
ConclusionsIDeg has a flat, consistent and ultra‐long glucose‐lowering effect that is evenly distributed across a 24‐hour interval and an ultra‐long duration of action in Japanese subjects with type 1 diabetes. These data support once‐daily dosing of IDeg in all patients. Overall, the pharmacodynamic and pharmacokinetic endpoints and safety observations are consistent with those previously reported in Caucasian subjects.This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Ippei Ikushima, Kohei Kaku, Koichi Hirao, Lars Bardtrum, Hanne Haahr Tags: Clinical Trial Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Eyes | Insulin | Levemir | Study